ClinicalTrials.gov
public full text
Public Domain
Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.
Until now, there is no effective approach to stop the progression of multiple sclerosis and stimulate re-myelination. Autologous stem cell transplantation shows hope and is quickly developing as an alternative therapy. We propose the use of autologous bone marrow-derived specific stem cell populations and mesenchymal stem cell transplantation (BM-MSC) associated with immuno-modulation to treat patients with relapsing-remitting MS (RRMS).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Cell therapy in multiple sclerosis: An overview#147484
- MEsenchymal StEm Cells for Multiple Sclerosis#910612
- IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study#902459
- Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.#454280
- The Impact of Body Weight on Clinical and Immunological Outcomes in Relapse-Remitting Multiple Sclerosis Patients#896282
Record · ID 884166
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive